The most prevalent reasons for exclusion included heparin infusion for less than 24 hours and inadequate protocol compliance. Inadequate protocol compliance was the reason for exclusion in 13 of ...

guidelines recommend that intravenous unfractionated heparin (UFH) be dosed by weight with a bolus dose of 60 U/kg to a maximum of 4000 U and an infusion dose of 12 U/kg/h to a maximum of 1000 U/h.

Finnish biopharmaceutical company Aplagon has secured a financing of €7m ($7.24m) to advance its heparin proteoglycan mimetic, APAC, to primarily support the initiation of a Phase IIa trial for ...

The results increase “my confidence that this approach has merit,” Lauren Sansing says. More trials are on the way.

Aplagon announces EUR 7 million financing to advance its APAC therapeutic for thrombo-inflammatory diseases into phase 2A trials: Helsinki Tuesday, February 4, 2025, 16:00 Hrs [IS ...

Helsinki-based Aplagon has raised EUR 7 million to advance its APAC therapeutic for thrombo-inflammatory diseases into phase 2a clinical trials. Aki Prihti, CEO of Aplagon, said: “We’re delighted to ...

Brittney Saunders Graves discusses the power of self-advocacy and why she refused to stay silent in the face of medical ...

The use of a postoperative heparin infusion (n=5) was associated with a higher rate of all complications (80.0% vs 11.1%, p=0.023) and symptomatic complications (60% vs 0.0%, p=0.028). No symptomatic ...

During this period, each center prospectively applied one of three periprocedural protocols: (a) two centers administered aspirin (250 mg IV); (b) one center administered aspirin and heparin (bolus+24 ...

2018.08.002 13. Grip O, Kuoppala M, Acosta S, et al. Outcome and complications after intra-arterial thrombolysis for lower limb ischaemia with or without continuous heparin infusion. Br J Surg.